{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:35:34Z","timestamp":1788867334676,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018047","name":"NRG Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005923","name":"International Association for the Study of Lung Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021088","name":"Clade Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01HL157273-01"],"award-info":[{"award-number":["1R01HL157273-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R37CA231522-02"],"award-info":[{"award-number":["5R37CA231522-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA261669"],"award-info":[{"award-number":["P01 CA261669"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008513","name":"Thomas Jefferson University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011981","name":"American College of Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011981","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.prro.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T04:21:32Z","timestamp":1681791692000},"page":"413-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Consensus Quality Measures and Dose Constraints for Lung Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and ASTRO Expert Panel"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2058-6953","authenticated-orcid":false,"given":"Lindsay L.","family":"Puckett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Titi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Kujundzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Dawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Katsoulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabh","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatinder","family":"Palta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrin J.","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma K.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Movsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Charles R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Werner-Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Kudner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2023.04.003_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2023.04.003_bib0002","unstructured":"U.S. Medicine. Understanding the breath-taking lung cancer risks in servicemembers, veterans. Available at: https:\/\/www.usmedicine.com\/supplement\/nsclc-supplement\/understanding-the-breath-taking-lung-cancer-risks-in-servicemembers-veterans\/#:\u223c:text=As%20common%20as%20it%20is,in%20those%20who%20never%20served. Accessed September 21, 2022."},{"key":"10.1016\/j.prro.2023.04.003_bib0003","doi-asserted-by":"crossref","first-page":"e1883","DOI":"10.7205\/MILMED-D-16-00371","article-title":"Cancer incidence among patients of the U.S. Veterans Affairs Health Care System: 2010 update","volume":"182","author":"Zullig","year":"2017","journal-title":"Mil Med"},{"key":"10.1016\/j.prro.2023.04.003_bib0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.semradonc.2014.11.001","article-title":"International patterns of radiotherapy practice for non-small cell lung cancer","volume":"25","author":"Vinod","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0005","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.prro.2022.05.015","article-title":"Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Quality Measures Initiative","volume":"12","author":"Park","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0006","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ijrobp.2019.08.064","article-title":"VA-Radiation Oncology Quality Surveillance Program","volume":"106","author":"Hagan","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.04.003_bib0007","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.prro.2022.08.018","article-title":"Consensus quality measures and dose constraints for prostate cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel","volume":"13","author":"Solanki","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0008","doi-asserted-by":"crossref","unstructured":"Puckett LL, Kodali D, Solanki AA, et al. Consensus quality measures and dose constraints for breast cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel [e-pub ahead of print]. Pract Radiat Oncol. https:\/\/doi.org\/10.1016\/j.prro.2022.08.016. Accessed Feburary 21, 2023.","DOI":"10.1016\/j.prro.2022.08.016"},{"key":"10.1016\/j.prro.2023.04.003_bib0009","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.prro.2022.05.005","article-title":"Consensus quality measures and dose constraints for rectal cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology (ASTRO) Expert Panel","volume":"12","author":"Park","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.prro.2022.05.009","volume":"12","author":"Katsoulakis","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0011","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0012","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","article-title":"Radiation therapy for small cell lung cancer: An ASTRO clinical practice guideline","volume":"10","author":"Simone","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0013","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijrobp.2020.05.012","article-title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement","volume":"107","author":"Guckenberger","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.04.003_bib0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/acm2.13308","article-title":"Automated data abstraction for quality surveillance and outcome assessment in radiation oncology","volume":"22","author":"Kapoor","year":"2021","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.prro.2023.04.003_bib0015","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: Stereotactic radiation for ultracentral non-small-cell lung cancer\u2014A safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"16 suppl","key":"10.1016\/j.prro.2023.04.003_bib0016","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1200\/JCO.2022.40.16_suppl.8513","article-title":"Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1\u2013high locally advanced non-small cell lung cancer","volume":"40","author":"Lin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0017","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0018","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijrobp.2015.07.2260","article-title":"A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927)","volume":"93","author":"Videtic","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2023.04.003_bib0019","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.04.003_bib0020","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2013.07.029","article-title":"Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis","volume":"87","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.04.003_bib0021","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.prro.2023.04.003_bib0022","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0023","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13014-016-0640-8","article-title":"Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: Phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC","volume":"11","author":"Giaddui","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ijrobp.2007.03.011","article-title":"Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"69","author":"Rice","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.04.003_bib0026","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15 suppl","key":"10.1016\/j.prro.2023.04.003_bib0027","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1200\/JCO.2020.38.15_suppl.9011","article-title":"Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer","volume":"38","author":"Kelly","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0028","unstructured":"ClinicalTrials.gov. Testing the addition of high dose, targeted radiation to the usual treatment for locally-advanced inoperable non-small cell lung cancer. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT05624996. Accessed December 15, 2022."},{"key":"10.1016\/j.prro.2023.04.003_bib0029","first-page":"5","article-title":"Standardization as a mechanism to improve safety in health care","volume":"30","author":"Rozich","year":"2004","journal-title":"Jt Comm J Qual Saf"},{"key":"10.1016\/j.prro.2023.04.003_bib0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.6004\/jnccn.2020.7536","article-title":"Quality measurement in cancer care: A review and endorsement of high-impact measures and concepts","volume":"18","author":"D'Amico","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.prro.2023.04.003_bib0031","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3816\/CLC.2009.n.046","article-title":"Quality indicators in cancer care: Development and implementation for improved health outcomes in non\u2013small-cell lung cancer","volume":"10","author":"Lennes","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.prro.2023.04.003_bib0032","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ijrobp.2011.12.079","article-title":"Quality assessment in oncology","volume":"83","author":"Albert","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.04.003_bib0033","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JMDH.S117945","article-title":"Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: An overview and synthesis of the available literature","volume":"11","author":"Soukup","year":"2018","journal-title":"J Multidiscip Healthc"},{"key":"10.1016\/j.prro.2023.04.003_bib0034","doi-asserted-by":"crossref","unstructured":"Maurice NM, Tanner NT. Lung cancer screening at the VA: Past, present and future [e-pub ahead of print]. Semin Oncol. https:\/\/doi.org\/10.1053\/j.seminoncol.2022.06.001. Accessed February 20, 2023.","DOI":"10.1053\/j.seminoncol.2022.06.001"},{"key":"10.1016\/j.prro.2023.04.003_bib0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.athoracsur.2016.07.003","article-title":"Quality measures in clinical stage I non-small cell lung cancer: Improved performance is associated with improved survival","volume":"103","author":"Samson","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.prro.2023.04.003_bib0036","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jtcvs.2018.09.126","article-title":"Evaluation of adherence to the Commission on Cancer lung cancer quality measures","volume":"157","author":"Odell","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.prro.2023.04.003_bib0037","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/JTO.0b013e31828cb548","article-title":"Improving the quality of lung cancer care in Ontario: The Lung Cancer Disease Pathway Initiative","volume":"8","author":"Evans","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0038","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1097\/JTO.0b013e3182a4070f","article-title":"Nationwide quality improvement in lung cancer care: The role of the Danish Lung Cancer Group and Registry","volume":"8","author":"Jakobsen","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"suppl 4","key":"10.1016\/j.prro.2023.04.003_bib0039","first-page":"S76","article-title":"Strategic initiatives for veterans with lung cancer","volume":"37","author":"Moghanaki","year":"2020","journal-title":"Fed Pract"},{"key":"10.1016\/j.prro.2023.04.003_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2020.08.017","article-title":"European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer","volume":"150","author":"Berghmans","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prro.2023.04.003_bib0041","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III non-small-cell lung cancer: ASCO Guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0042","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/0284186X.2019.1675907","article-title":"Hypofractionated versus conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy","volume":"59","author":"Iocolano","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0043","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC Trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0044","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic body radiation therapy for operable early-stage lung cancer: Findings from the NRG Oncology RTOG 0618 trial","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7 suppl 3","key":"10.1016\/j.prro.2023.04.003_bib0045","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0046","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.04.003_bib0047","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","article-title":"American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy","volume":"76","author":"Potters","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023001078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023001078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:25:46Z","timestamp":1761819946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850023001078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1879850023001078"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2023.04.003","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus Quality Measures and Dose Constraints for Lung Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and ASTRO Expert Panel","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}